Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival.

Cartlidge RA, Thomas GR, Cagnol S, Jong KA, Molton SA, Finch AJ, McMahon M.

Pigment Cell Melanoma Res. 2008 Oct;21(5):534-44. doi: 10.1111/j.1755-148X.2008.00491.x. Epub 2007 Jul 28.

2.

Pten deficiency in melanocytes results in resistance to hair graying and susceptibility to carcinogen-induced melanomagenesis.

Inoue-Narita T, Hamada K, Sasaki T, Hatakeyama S, Fujita S, Kawahara K, Sasaki M, Kishimoto H, Eguchi S, Kojima I, Beermann F, Kimura T, Osawa M, Itami S, Mak TW, Nakano T, Manabe M, Suzuki A.

Cancer Res. 2008 Jul 15;68(14):5760-8. doi: 10.1158/0008-5472.CAN-08-0889.

3.

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.

Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, García-Echeverría C.

Mol Cancer Ther. 2008 Jul;7(7):1851-63. doi: 10.1158/1535-7163.MCT-08-0017. Epub 2008 Jul 7.

4.

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation.

Lutzky J, Bauer J, Bastian BC.

Pigment Cell Melanoma Res. 2008 Aug;21(4):492-3. doi: 10.1111/j.1755-148X.2008.00475.x. Epub 2008 May 29. No abstract available.

PMID:
18510589
5.

Oncogenic B-RafV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim.

Sheridan C, Brumatti G, Martin SJ.

J Biol Chem. 2008 Aug 8;283(32):22128-35. doi: 10.1074/jbc.M800271200. Epub 2008 May 27.

6.

Major response to imatinib mesylate in KIT-mutated melanoma.

Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE.

J Clin Oncol. 2008 Apr 20;26(12):2046-51. doi: 10.1200/JCO.2007.14.0707. No abstract available.

7.

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.

Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K, Li L, Smalley KS, Fong D, Zhu YL, Marimuthu A, Nguyen H, Lam B, Liu J, Cheung I, Rice J, Suzuki Y, Luu C, Settachatgul C, Shellooe R, Cantwell J, Kim SH, Schlessinger J, Zhang KY, West BL, Powell B, Habets G, Zhang C, Ibrahim PN, Hirth P, Artis DR, Herlyn M, Bollag G.

Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3041-6. doi: 10.1073/pnas.0711741105. Epub 2008 Feb 19.

8.

Modeling genomic diversity and tumor dependency in malignant melanoma.

Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, Laine E, Greulich H, Tseng H, Gates C, Hodi FS, Dranoff G, Sellers WR, Thomas RK, Meyerson M, Golub TR, Dummer R, Herlyn M, Getz G, Garraway LA.

Cancer Res. 2008 Feb 1;68(3):664-73. doi: 10.1158/0008-5472.CAN-07-2615.

9.

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.

Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S, Marlow A, Hurley B, Lyssikatos J, Lee PA, Winkler JD, Koch K, Wallace E.

Clin Cancer Res. 2007 Mar 1;13(5):1576-83.

10.

A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors.

Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M.

Genes Dev. 2007 Feb 15;21(4):379-84. Epub 2007 Feb 13.

11.

Genomic profiling of malignant melanoma using tiling-resolution arrayCGH.

Jönsson G, Dahl C, Staaf J, Sandberg T, Bendahl PO, Ringnér M, Guldberg P, Borg A.

Oncogene. 2007 Jul 12;26(32):4738-48. Epub 2007 Jan 29.

PMID:
17260012
12.

The use of targeted mouse models for preclinical testing of novel cancer therapeutics.

Olive KP, Tuveson DA.

Clin Cancer Res. 2006 Sep 15;12(18):5277-87. Review.

13.

Malignant melanoma: genetics and therapeutics in the genomic era.

Chin L, Garraway LA, Fisher DE.

Genes Dev. 2006 Aug 15;20(16):2149-82. Review.

14.

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.

Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, Nathanson KL, Xia C, Simantov R, Schwartz B, Poulin-Costello M, O'Dwyer PJ, Ratain MJ.

Br J Cancer. 2006 Sep 4;95(5):581-6. Epub 2006 Aug 1.

15.

MC1R germline variants confer risk for BRAF-mutant melanoma.

Landi MT, Bauer J, Pfeiffer RM, Elder DE, Hulley B, Minghetti P, Calista D, Kanetsky PA, Pinkel D, Bastian BC.

Science. 2006 Jul 28;313(5786):521-2. Epub 2006 Jun 29.

16.

Characterization of melanocyte-specific inducible Cre recombinase transgenic mice.

Bosenberg M, Muthusamy V, Curley DP, Wang Z, Hobbs C, Nelson B, Nogueira C, Horner JW 2nd, Depinho R, Chin L.

Genesis. 2006 May;44(5):262-7.

PMID:
16676322
17.

BRAF and c-kit gene copy number in mutation-positive malignant melanoma.

Willmore-Payne C, Holden JA, Hirschowitz S, Layfield LJ.

Hum Pathol. 2006 May;37(5):520-7.

PMID:
16647948
18.

Molecular targets in melanoma from angiogenesis to apoptosis.

Sosman JA, Puzanov I.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2376s-2383s. Review.

19.

Chemotherapy and targeted therapy combinations in advanced melanoma.

Flaherty KT.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2366s-2370s. Review.

20.

The WNT/Beta-catenin pathway in melanoma.

Larue L, Delmas V.

Front Biosci. 2006 Jan 1;11:733-42. Review.

PMID:
16146765
Items per page

Supplemental Content

Write to the Help Desk